CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Cartesian Therapeutics, Inc. (RNAC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Cartesian Therapeutics, Inc. (RNAC)

Pharmaceutical Preparations · market cap $232M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Cartesian Therapeutics (RNAC) is a small-cap biotech (66 employees, ~$190M market cap, ~$6.28/share) whose lead asset, listed as Decartes-08 / Descartes-08 in our data, is in Phase 3 for myasthenia gravis. The same asset is also listed in Phase 2 for systemic lupus erythematosus, and Descartes 11 is in Phase 2 for multiple myeloma. Our calendar shows an estimated Phase 3 readout on 2026-12-30 (importance 9/10), preceded by an estimated Phase 2 event on 2026-12-01 and earnings on 2026-11-05.
The catalyst path
  • 2026-12-01 (est.)Phase 2 · Descartes-08imp 7/10
  • 2026-12-30 (est.)Phase 3 · Decartes-08imp 9/10
Pipeline
AssetPhaseIndication
Descartes-08Phase 2Systemic Lupus Erythematosus (SLE)
Descartes 11Phase 2Multiple Myeloma
Decartes-08Phase 3Myasthaenia Gravis
Price & technical context
3-month
-23.4%
6-month
-16.9%
12-month
-12.1%
52-wk range
$5.84–$10.59
vs 50-day MA
-9.0%
vs 200-day MA
-11.2%
Realized vol
80.7%
Max drawdown
-76.8%

Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for RNAC (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.